Advances in the Epidemiology of Heart Failure and Left Ventricular Remodeling
2011; Lippincott Williams & Wilkins; Volume: 124; Issue: 20 Linguagem: Inglês
10.1161/circulationaha.111.070235
ISSN1524-4539
AutoresSusan Cheng, Ramachandran S. Vasan,
Tópico(s)Cardiac Valve Diseases and Treatments
ResumoHomeCirculationVol. 124, No. 20Advances in the Epidemiology of Heart Failure and Left Ventricular Remodeling Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBAdvances in the Epidemiology of Heart Failure and Left Ventricular Remodeling Susan Cheng, MD and Ramachandran S. Vasan, MD Susan ChengSusan Cheng From the Framingham Heart Study, Framingham, MA (S.C., R.S.V.); Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.C.); Cardiology Section, Boston University School of Medicine, Boston, MA (R.S.V.); and Preventive Medicine Section, Boston University School of Medicine, Boston, MA (R.S.V.). and Ramachandran S. VasanRamachandran S. Vasan From the Framingham Heart Study, Framingham, MA (S.C., R.S.V.); Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.C.); Cardiology Section, Boston University School of Medicine, Boston, MA (R.S.V.); and Preventive Medicine Section, Boston University School of Medicine, Boston, MA (R.S.V.). Originally published15 Nov 2011https://doi.org/10.1161/CIRCULATIONAHA.111.070235Circulation. 2011;124:e516–e519Heart failure (HF) continues to impose a major public health burden.1 Whereas considerable improvements in HF treatment have resulted from clinical trials, epidemiological investigations complement clinical trials by enhancing our ability to identify individuals at risk and, in turn, facilitate the development of interventions aimed at the primary prevention of HF. Accordingly, there have been several noteworthy advances to date in the epidemiology of heart failure and subclinical myocardial disease, which are summarized below.Dynamic Left Ventricular Remodeling Over the Life CourseAdverse left ventricular (LV) remodeling is considered an intermediate phenotype of HF, given the high incidence of HF events observed among individuals with subclinical abnormalities in LV structure or function (also known as stage B heart failure).2 Recent investigations have harnessed longitudinal data from large epidemiological cohorts to examine how the heart remodels over the adult life course and to characterize the factors that contribute to this remodeling. The most common form of adverse LV remodeling is increased LV mass, which has long been associated with incident HF; this association was originally demonstrated with the use of electrocardiography, followed by echocardiography, and then recently confirmed using cardiac MRI studies.3,4 Longitudinal data have now validated the results of previous cross-sectional studies indicating that LV mass progressively increases over the life course, and particularly in the presence of risk factors such as obesity, hypertension, and diabetes.5 However, increased LV mass can result from a variety of different remodeling patterns, including concentric or eccentric changes in geometry.6,7 The most common remodeling pattern observed in normally aging individuals over the life course is a concentric remodeling pattern, in which LV wall thickness progressively increases and LV cavity dimensions progressively decrease in the setting of preserved and increasing ejection fraction.3,8 Interestingly, the rate of increase in relative wall thickness is more pronounced in women compared with with men across all ages, especially in later life. This finding may be related to intriguing histological evidence of less cardiomyocyte dropout and slightly higher cardiomyocyte turnover observed in aging women in comparison with men.9,10 These sex differences may also account for the higher prevalence of concomitantly increased ventricular and vascular stiffness observed in older women versus men living in the community.11However, the extent to which the concentric remodeling pattern of normal aging contributes to the lifetime risk of HF12 is far from clear. The presence of conventional risk factors for HF actually serves to modify this typical remodeling pattern. For instance, in the setting of obesity, hypertension, and diabetes mellitus, LV wall thickness remains increased, but cavity dimensions do not decrease proportionately with age.8 This likely reflects an impaired compensatory response to increased wall stress, which is evidenced by a less robust increase in ejection fraction over time. That said, absolute values of LV ejection fraction remain invariably in the normal range, indicating that morphological changes in cardiac structure can be accompanied by subclinical changes in cardiac performance that are not reflected by major changes in ejection fraction.13,14 Indeed, both concentric and eccentric cardiac phenotypes are known to include subphenotypes characterized by better or worse function.7 And, concordant with evidence of progressive age-associated increases in left atrial size,15 conventional measures of diastolic dysfunction are highly prevalent among middle-aged and older adults in the community16,17 and have been shown to increase risk for HF.17,18 Thus, further work is needed to clarify the functional changes that occur as LV geometry evolves over time, with and without exposure to traditional risk factors, and how these changes contribute to HF risk.The impact of novel risk factors on LV remodeling also warrants further study. In addition to traditional risk factors, recent data have associated dyslipidemia,19 physical inactivity/abdominal obesity,20,21 and sleep apnea22 with increased risk for HF in the community. Other recent investigations have demonstrated a familial aggregation of LV geometric phenotypes, particularly concentric LV hypertrophy.23 Family history of HF has also been associated with a greater odds of eccentric LV geometry in offspring free of HF.23 Thus, future studies should consider the genetic influences of LV remodeling, in parallel with the study of nongenetic determinants.Beyond the Left Ventricle: Extracardiac Predictors of HF RiskNotwithstanding the centrality of subclinical LV disease in the development of HF, recent clinical investigations have shed light on the importance of extracardiac contributors to HF risk. It is well known that the LV functions in physiological equilibrium with the right heart,24 the pulmonary circuit,25 and other major organ systems. Accordingly, adverse LV remodeling and dysfunction have been associated with pulmonary airflow obstruction26 and decreased renal function27 in cross-sectional studies; abnormalities in serum creatinine,28,29 albumin,28,29 and hemoglobin30 have also been associated with HF risk and/or worse HF outcomes. Until recently, however, extracardiac contributions to subclinical LV disease and dysfunction had not been investigated comprehensively. In a large community-based sample, Lam and colleagues examined markers of subclinical dysfunction of several noncardiac organ systems and reported that the ratio of lower forced expiratory volume in the first second to forced vital capacity ratios, hemoglobin, and higher serum creatinine were each associated with a 30% increased risk of incident HF after adjustment for conventional HF risk factors.17 Interestingly, renal dysfunction and anemia were particularly associated with incidence of HF with reduced ejection fraction whereas pulmonary obstructive disease was particularly associated with incidence of HF with preserved ejection fraction. Still, the strongest predictors of incident HF with reduced ejection fraction and HF with preserved ejection fraction were asymptomatic systolic and diastolic dysfunction, respectively. Thus, the extent to which subclinical cardiac dysfunction promotes subclinical noncardiac dysfunction, or vice versa, remains unclear. However, these findings underscore the fact that progression to HF is likely a multiorgan, multisystemic process.31 Further research is needed to define the interdependent hemodynamic, neurohormonal, paracrine, and/or other mechanisms that underlie the interactions between cardiac and noncardiac organ systems.Biomarkers of LV Remodeling and HFBiological markers can be used to classify subclinical disease phenotypes and for prognostication, as well.7,32 In addition, biomarkers can also be used to provide insight regarding the pathobiology of both LV remodeling and HF.33,34 Although there have been few systematic investigations of multiple pathway markers, recently published studies have identified markers reflecting activity of select biological pathways that are associated with LV remodeling and with incident HF. Velagaleti and colleagues found that biomarkers of inflammation (C-reactive protein), hemostasis (fibrinogen and plasminogen activator inhihibitor-1), and activation of the renin-angiotensin-aldosterone system (aldosterone-to-renin ratio) were each associated with LV geometry in separate models.35 However, only the aldosterone-to-renin ratio was associated with both eccentric and concentric LV hypertrophy when all biomarkers were included in the same model. The same investigators applied a similar multimarker strategy to investigate predictors of incident HF and observed that only the B-type natriuretic peptide and the urinary albumin-to-creatinine ratio emerged as significant predictors of nonischemic HF risk in analyses that also included C-reactive protein, plasminogen activator inhihibitor-1, homocysteine, and aldosterone-to-renin ratio.36 These findings are consistent with previous literature suggesting that markers of renin-angiotensin-aldosterone system activation are more strongly associated with LV remodeling parameters,37 whereas B-type natriuretic peptide is more widely recognized as a risk predictor of overt HF.38 Both of these pathways have been targeted for therapeutic interventions (eg, pharmacological modulation of the renin-angiotensin-aldosterone system versus natriuretic peptide pathways).39–43 Extending from this work, recent studies have identified alternate putative biomarkers of subclinical LV disease (eg, adiponectin44) and HF risk (eg, growth differentiation factor-1545 and markers of fibrosis46). An additional area of intense research is the search for common genetic variants that may underlie LV remodeling,47,48 incident HF,49 and mortality after the onset of HF.50,51 The potential role of these newer biomarkers as targets remains to be determined. It is conceivable that both genetic and circulating biomarkers could be combined with standard risk factors for predicting HF risk or for identifying individuals at risk of developing adverse LV remodeling and/or subclinical LV dysfunction. Important information will also accrue from ongoing experimental studies that are investigating alterations in myocardial gene expression patterns in cardiac hypertrophy and HF,52 and have demonstrated reciprocal changes in metabolic and signaling pathways in the myocardium with increasing severity of HF.53ConclusionIn summary, recent epidemiological investigations have provided several key insights regarding LV remodeling and HF risk. First, the LV undergoes progressive morphological changes over the adult life course, characterized by a concentric remodeling pattern that is modified in the setting of exposure to traditional and novel risk factors, on a background of genetic determinants that have yet to be fully identified. The extent to which the normal aging pattern of LV remodeling leads to eventual LV dysfunction and the time course of such evolution remains unclear. Second, the subclinical abnormalities leading up to clinical HF are not limited to the LV, but include alterations involving the right heart and other key organ systems, highlighting that chronic noncardiac processes are developing in concert with subclinical LV remodeling and dysfunction in the progression to clinical HF. Finally, biomarkers representing the activity of select biological pathways appear associated with both LV remodeling and the propensity for HF. These same pathways could also underlie the interdependent contributions of cardiac and noncardiac dysfunction to HF risk. Ongoing genomic and gene expression studies are likely to augment investigations of these candidate pathways as well highlight previously unidentified targets for further research. Taken together, recent developments in epidemiological research have provided a wealth of additional insights into the precursors of HF and will, hopefully, continue to fuel ongoing discovery and development of preventive therapies.Sources of FundingThis work was supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (contract N01-HC-25195) and grant R01HL093328.DisclosuresNone.FootnotesCorrespondence to Ramachandran S. Vasan, MD, The Framingham Heart Study, 73 Mount Wayte Ave, Suite 2, Framingham, MA 01702-5803. E-mail [email protected]eduReferences1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011; 123:e18–e209.LinkGoogle Scholar2. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119:1977–2016.LinkGoogle Scholar3. Cheng S, Fernandes VR, Bluemke DA, McClelland RL, Kronmal RA, Lima JA. Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging. 2009; 2:191–198.LinkGoogle Scholar4. Jain A, McClelland RL, Polak JF, Shea S, Burke GL, Bild DE, Watson KE, Budoff MJ, Liu K, Post WS, Folsom AR, Lima JA, Bluemke DA. Cardiovascular imaging for assessing cardiovascular risk in asymptomatic men versus women: the Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging. 2011; 4:8–15.LinkGoogle Scholar5. Lieb W, Xanthakis V, Sullivan LM, Aragam J, Pencina MJ, Larson MG, Benjamin EJ, Vasan RS. Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the Framingham offspring study. Circulation. 2009; 119:3085–3092.LinkGoogle Scholar6. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011; 123:327–334.LinkGoogle Scholar7. Khouri MG, Peshock RM, Ayers CR, de Lemos JA, Drazner MH. A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study. Circ Cardiovasc Imaging. 2010; 3:164–171.LinkGoogle Scholar8. Cheng S, Xanthakis V, Sullivan LM, Lieb W, Massaro J, Aragam J, Benjamin EJ, Vasan RS. Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Circulation. 2010; 122:570–578.LinkGoogle Scholar9. Kajstura J, Gurusamy N, Ogorek B, Goichberg P, Clavo-Rondon C, Hosoda T, D'Amario D, Bardelli S, Beltrami AP, Cesselli D, Bussani R, del Monte F, Quaini F, Rota M, Beltrami CA, Buchholz BA, Leri A, Anversa P. Myocyte turnover in the aging human heart. Circ Res. 2010; 107:1374–1386.LinkGoogle Scholar10. Porrello ER, Olson EN. Building a new heart from old parts: stem cell turnover in the aging heart. Circ Res. 2010; 107:1292–1294.LinkGoogle Scholar11. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation. 2005; 112:2254–2262.LinkGoogle Scholar12. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002; 106:3068–3072.LinkGoogle Scholar13. Rosen BD, Fernandes VR, Nasir K, Helle-Valle T, Jerosch-Herold M, Bluemke DA, Lima JA. Age, increased left ventricular mass, and lower regional myocardial perfusion are related to greater extent of myocardial dyssynchrony in asymptomatic individuals: the Multi-Ethnic Study of Atherosclerosis. Circulation. 2009; 120:859–866.LinkGoogle Scholar14. Rosen BD, Edvardsen T, Lai S, Castillo E, Pan L, Jerosch-Herold M, Sinha S, Kronmal R, Arnett D, Crouse JR, Heckbert SR, Bluemke DA, Lima JA. Left ventricular concentric remodeling is associated with decreased global and regional systolic function: the Multi-Ethnic Study of Atherosclerosis. Circulation. 2005; 112:984–991.LinkGoogle Scholar15. McManus DD, Xanthakis V, Sullivan LM, Zachariah J, Aragam J, Larson MG, Benjamin EJ, Vasan RS. Longitudinal tracking of left atrial diameter over the adult life course: clinical correlates in the community. Circulation. 2010; 121:667–674.LinkGoogle Scholar16. Kuznetsova T, Herbots L, Lopez B, Jin Y, Richart T, Thijs L, Gonzalez A, Herregods MC, Fagard RH, Diez J, Staessen JA. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail. 2009; 2:105–112.LinkGoogle Scholar17. Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, Levy D, Redfield MM, Pieske BM, Benjamin EJ, Vasan RS. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation. 2011; 124:24–30.LinkGoogle Scholar18. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC, Jacobsen SJ, Rodeheffer RJ. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA. 2011; 306:856–863.CrossrefMedlineGoogle Scholar19. Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D. Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. Circulation. 2009; 120:2345–2351.LinkGoogle Scholar20. Hu G, Jousilahti P, Antikainen R, Katzmarzyk PT, Tuomilehto J. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010; 121:237–244.LinkGoogle Scholar21. Kenchaiah S, Sesso HD, Gaziano JM. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation. 2009; 119:44–52.LinkGoogle Scholar22. Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, Shahar E. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010; 122:352–360.LinkGoogle Scholar23. Lam CS, Liu X, Yang Q, Larson MG, Pencina MJ, Aragam J, Redfield MM, Benjamin EJ, Vasan RS. Familial aggregation of left ventricular geometry and association with parental heart failure: the Framingham Heart Study. Circ Cardiovasc Genet. 2010; 3:492–498.LinkGoogle Scholar24. Drazner MH, Prasad A, Ayers C, Markham DW, Hastings J, Bhella PS, Shibata S, Levine BD. The relationship of right- and left-sided filling pressures in patients with heart failure and a preserved ejection fraction. Circ Heart Fail. 2010; 3:202–206.LinkGoogle Scholar25. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009; 119:2663–2670.LinkGoogle Scholar26. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, Shahar E, Smith LJ, Watson KE. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010; 362:217–227.CrossrefMedlineGoogle Scholar27. Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA, Balko JA, Gupta S, Mammen PP, Drazner MH, Markham DW. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail. 2009; 2:98–104.LinkGoogle Scholar28. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, Satterfield S, Smith AL, Vaccarino V, Newman AB, Harris TB, Wilson PW, Kritchevsky SB. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail. 2008; 1:125–133.LinkGoogle Scholar29. Kalogeropoulos A, Psaty BM, Vasan RS, Georgiopoulou V, Smith AL, Smith NL, Kritchevsky SB, Wilson PW, Newman AB, Harris TB, Butler J. Validation of the health ABC heart failure model for incident heart failure risk prediction: the Cardiovascular Health Study. Circ Heart Fail. 2010; 3:495–502.LinkGoogle Scholar30. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004; 110:149–154.LinkGoogle Scholar31. Klein L. Omnes viae romam ducunt: asymptomatic cardiac and noncardiac organ system dysfunction leads to heart failure. Circulation. 2011; 124:4–6.LinkGoogle Scholar32. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC, Wilson PW. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009; 119:2408–2416.LinkGoogle Scholar33. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007; 115:949–952.LinkGoogle Scholar34. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation. 2011; 123:551–565.LinkGoogle Scholar35. Velagaleti RS, Gona P, Levy D, Aragam J, Larson MG, Tofler GH, Lieb W, Wang TJ, Benjamin EJ, Vasan RS. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation.2008; 118:2252–2258;5 p following 2258.LinkGoogle Scholar36. Velagaleti RS, Gona P, Larson MG, Wang TJ, Levy D, Benjamin EJ, Selhub J, Jacques PF, Meigs JB, Tofler GH, Vasan RS. Multimarker approach for the prediction of heart failure incidence in the community. Circulation. 2010; 122:1700–1706.LinkGoogle Scholar37. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, Wilson PW. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension. 2004; 43:957–962.LinkGoogle Scholar38. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, Nelson RW, Schellenberger U. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2008; 1:258–264.LinkGoogle Scholar39. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008; 1:17–24.LinkGoogle Scholar40. Burnett JC, Korinek J. The tumultuous journey of nesiritide: past, present, and future. Circ Heart Fail. 2008; 1:6–8.LinkGoogle Scholar41. Cataliotti A, Tonne JM, Bellavia D, Martin FL, Oehler EA, Harders GE, Campbell JM, Peng KW, Russell SJ, Malatino LS, Burnett JC, Ikeda Y. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation. 2011; 123:1297–1305.LinkGoogle Scholar42. Costello-Boerrigter LC, Boerrigter G, Cataliotti A, Harty GJ, Burnett JCRenal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.Circ Heart Fail. 2010; 3:412–419.LinkGoogle Scholar43. Cataliotti A, Chen HH, Schirger JA, Martin FL, Boerrigter G, Costello-Boerrigter LC, James KD, Polowy K, Miller MA, Malkar NB, Bailey KR, Burnett JCChronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension.Circulation. 2008; 118:1729–1736.LinkGoogle Scholar44. Bidulescu A, Liu J, Musani SK, Fox ER, Samdarshi TE, Sarpong DF, Vaccarino V, Wilson PW, Arnett DK, Din-Dzietham R, Taylor HA, Gibbons GHAssociation of adiponectin with left ventricular mass in African Americans: the Jackson Heart Study.Circ Heart Fail.August 12, 2011.doi: 10.1161/CIRCHEARTFAILURE.110.959742. Available at: http://ahajournals.org.Google Scholar45. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010; 122:1387–1395.LinkGoogle Scholar46. Barasch E, Gottdiener JS, Aurigemma G, Kitzman DW, Han J, Kop WJ, Tracy RP. Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ Heart Fail. 2009; 2:303–310.LinkGoogle Scholar47. Vasan RS, Glazer NL, Felix JF, Lieb W, Wild PS, Felix SB, Watzinger N, Larson MG, Smith NL, Dehghan A, Grosshennig A, Schillert A, Teumer A, Schmidt R, Kathiresan S, Lumley T, Aulchenko YS, Konig IR, Zeller T, Homuth G, Struchalin M, Aragam J, Bis JC, Rivadeneira F, Erdmann J, Schnabel RB, Dorr M, Zweiker R, Lind L, Rodeheffer RJ, Greiser KH, Levy D, Haritunians T, Deckers JW, Stritzke J, Lackner KJ, Volker U, Ingelsson E, Kullo I, Haerting J, O'Donnell CJ, Heckbert SR, Stricker BH, Ziegler A, Reffelmann T, Redfield MM, Werdan K, Mitchell GF, Rice K, Arnett DK, Hofman A, Gottdiener JS, Uitterlinden AG, Meitinger T, Blettner M, Friedrich N, Wang TJ, Psaty BM, van Duijn CM, Wichmann HE, Munzel TF, Kroemer HK, Benjamin EJ, Rotter JI, Witteman JC, Schunkert H, Schmidt H, Volzke H, Blankenberg S. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA. 2009; 302:168–178.CrossrefMedlineGoogle Scholar48. Sarwar R, Cook SA. Genomic analysis of left ventricular remodeling. Circulation. 2009; 120:437–444.LinkGoogle Scholar49. Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, Loehr LR, Cupples LA, Dehghan A, Lumley T, Rosamond WD, Lieb W, Rivadeneira F, Bis JC, Folsom AR, Benjamin E, Aulchenko YS, Haritunians T, Couper D, Murabito J, Wang YA, Stricker BH, Gottdiener JS, Chang PP, Wang TJ, Rice KM, Hofman A, Heckbert SR, Fox ER, O'Donnell CJ, Uitterlinden AG, Rotter JI, Willerson JT, Levy D, van Duijn CM, Psaty BM, Witteman JC, Boerwinkle E, Vasan RS. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet. 2010; 3:256–266.LinkGoogle Scholar50. Morrison AC, Felix JF, Cupples LA, Glazer NL, Loehr LR, Dehghan A, Demissie S, Bis JC, Rosamond WD, Aulchenko YS, Wang YA, Haritunians T, Folsom AR, Rivadeneira F, Benjamin EJ, Lumley T, Couper D, Stricker BH, O'Donnell CJ, Rice KM, Chang PP, Hofman A, Levy D, Rotter JI, Fox ER, Uitterlinden AG, Wang TJ, Psaty BM, Willerson JT, van Duijn CM, Boerwinkle E, Witteman JC, Vasan RS, Smith NL. Genomic variation associated with mortality among adults of European and African ancestry with heart failure: the cohorts for heart and aging research in genomic epidemiology consortium. Circ Cardiovasc Genet. 2010; 3:248–255.LinkGoogle Scholar51. McNamara DM, London B. GWAS applied to heart failure: bigger will be better eventually. Circ Cardiovasc Genet. 2010; 3:226–228.LinkGoogle Scholar52. Dewey FE, Perez MV, Wheeler MT, Watt C, Spin J, Langfelder P, Horvath S, Hannenhalli S, Cappola TP, Ashley EA. Gene coexpression network topology of cardiac development, hypertrophy, and failure. Circ Cardiovasc Genet. 2011; 4:26–35.LinkGoogle Scholar53. Barth AS, Kumordzie A, Frangakis C, Margulies KB, Cappola TP, Tomaselli GFReciprocal transcriptional regulation of metabolic and signaling pathways correlates with disease severity in heart failure.Circ Cardiovasc Genet.August 9, 2011.doi: 10.1161/CIRCGENETICS.110.957571. Available at: http://ahajournals.org.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Kour B, Gupta S, Singh R, Sophiarani Y and Paul P (2022) Interplay between circular RNA, microRNA, and human diseases, Molecular Genetics and Genomics, 10.1007/s00438-022-01856-8, 297:2, (277-286), Online publication date: 1-Mar-2022. Lima A, Formiga M, Giollo L, da Silva M, da Silva V, Otto M, Chiappa G and Cipriano G (2021) Arterial stiffness and pulse wave morphology in Chagas heart failure: insights from noninvasive applanation tonometry, Journal of Cardiovascular Medicine, 10.2459/JCM.0000000000001287, 23:1, (e36-e38), Online publication date: 1-Jan-2022. Ni Y, Deng J, Bai H, Liu C, Liu X and Wang X (2021) CaMKII inhibitor KN‐93 impaired angiogenesis and aggravated cardiac remodelling and heart failure via inhibiting NOX2/mtROS/p‐VEGFR2 and STAT3 pathways, Journal of Cellular and Molecular Medicine, 10.1111/jcmm.17081, 26:2, (312-325), Online publication date: 1-Jan-2022. Wang H, Du B, Wu Y, Li Z, Niu Y, Ouyang F, Wang J, Chen S and Sun K (2021) Sex-Disparity in the Association Between Birthweight and Cardiovascular Parameters in 4-Year-Old Children: A Chinese Cohort Study, Frontiers in Nutrition, 10.3389/fnut.2021.756512, 8 Arjunan P and D'Souza
Referência(s)